Global Peptide and Anticoagulant Drugs Market Research Report, by Type (Antibiotic, ACE Inhibitor, and Glatiramer Acetate), Application (Diabetes and Cancer) End Users (Hospital and Clinics, Research Centers, Diagnostic Center) – Global Forecast Till 2023

Market Scenario
Anticoagulants are referred to as blood thinners. It is a chemical substance that prevents or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals, it helps to keep the bitten area unclotted long enough for the animal to obtain some blood. Anticoagulants are related to and thrombolytic drugs and antiplatelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market. According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014. Global prevalence of diabetes in adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period. However, the higher price of NOACs and lack of antidots for NOACs impede the market growth.

Segmentation
The global peptide and anticoagulant drugs market is segmented on the basis of type, application and end users. The peptide and anticoagulant drugs market by type is hormonal, antibiotic, ACE inhibitor antifungal, other peptide drugs, and anticoagulants. Hormonal is sub-segmented into categorized into insulin teriparatide and leuprolide acetate. Antibiotic is categorized into eptifibatide and warfarin. On the basis of anticoagulants, the market is sub-segmented into enoxaparin sodium and heparin sodium. and on the basis of application, the market is sub-segmented into diabetes, cancer, infectious diseases, cancer, osteoporosis, cardiology, gynecology, other. On the basis of end users, the market is segmented into hospitals, research centers, and diagnostic centers.

On the basis of region, the global peptide and anticoagulant drugs market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. According to the cancer organization in 2017, it was found that 63,410 new cases of breast carcinoma in situ, 252,710 new cases of invasive breast cancer, and 40,610 breast cancer deaths.

The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players for peptide and anticoagulant drugs market
Some of the key players in the global peptide drugs market are Abbott Laboratories (U.S.), Cadila Pharmaceuticals (India), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Lupin Limited
Regional Market Summary

Global Peptide and Anticoagulant Drugs Market Share (%), by Region, 2017

Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health

It is estimated that North America dominated the global peptide and anticoagulant drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. According to WHO it was estimated that diabetes was the cause of 1.6 million deaths. Most of all deaths related to high blood glucose occur before the age of 70 years. WHO also projected that diabetes will be the seventh leading cause of death in 2030 which can be the major leading factor in the growth of peptide and anticoagulant drugs market in this region.

Europe stood second largest in the peptide and anticoagulant drugs market owing to the increasing use of tobacco. According to the Cancer Research UK, 359,960 cases of cancer were found in 2015. Also, 35,620 deaths caused due to lung cancer in this region due to change in lifestyle which can enhance the growth of peptide and anticoagulant drugs market.

Asia-Pacific was projected to be the fastest growing region for the global peptide and anticoagulant drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The international diabetes federation estimated 72,946,400 cases of diabetes in India in 2017. Such a high incidence of diabetes cases favors the market growth in this region.

The Middle East and Africa holds the least share in the global peptide and anticoagulant drugs market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

Intended Audience

- Pharmaceutical companies
- Peptide and anticoagulant drugs manufacturers
- Peptide and anticoagulant drugs marketing players
- Peptide and anticoagulant drugs distributors
- Various research and consulting companies

Market Segmentation

Global Peptide and anticoagulant drugs Market, by Type

- Hormonal
- Insulin
- Teriparatide
Leuprolide Acetate  
Antibiotic  
Eptifibatide  
Warfarin  
ACE Inhibitor  
Antifungal  
Other Peptide Drugs  
Anticoagulants  
Enoxaparin Sodium  
Heparin Sodium  
Others

Global Peptide and anticoagulant drugs Market, by Application

- Diabetes  
- Infectious Diseases  
- Cancer  
- Osteoporosis  
- Cardiology  
- Gynecology  
- Others

Global Peptide and anticoagulant drugs Market, by End-Users

- Introduction  
- Hospitals and clinics  
- Research Centers  
- Diagnostic Centers

Global Peptide and Anticoagulant Drugs Market, by Region

- Americas  
- Europe  
- Asia-Pacific  
- Middle East & Africa

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations

Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation

Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Peptide and anticoagulant drugs Market, by Type
6.1 Introduction
6.2 Hormonal
6.2.1 Insulin
6.2.2 Teriparatide
6.2.3 Leuprolide Acetate
6.3 Antibiotic
6.3.1 Eptifibatide
6.3.2 Warfarin
6.4 ACE Inhibitor
6.5 Antifungal
6.6 Other Peptide Drugs
6.7 Anticoagulants
6.7.1 Enoxaparin Sodium
6.7.2 Heparin Sodium
6.7.3 Others

Chapter 7. Global Peptide and anticoagulant drugs Market, by Application
7.1 Introduction
7.2 Diabetes
7.3 Infectious Diseases
7.4 Cancer
7.5 Osteoporosis
7.6 Cardiology
7.7 Gynecology
7.8 Others

Chapter 8. Global Peptide and anticoagulant drugs Market, by End-Users
8.1 Introduction
8.2 Hospitals and clinics
8.3 Research centers
8.4 Diagnostic Centers

Chapter 9. Global Peptide and anticoagulant drugs Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles
11.1 Abbott Laboratories Company
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 Cadila Pharmaceuticals
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Sanofi S.A.
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Peptide and anticoagulant drugs Market Industry Synopsis, 2018–2023
Table 2 Global Peptide and anticoagulant drugs Market Estimates & Forecast, 2018–2023, (USD Million)
Table 3 Global Peptide and anticoagulant drugs Market, by Region, 2018–2023, (USD Million)
Table 4 Global Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 5 Global Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 6 Global Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 7 North America: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 8 North America: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 9 North America: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 10 US: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 11 US: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 12 US: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 13 Canada: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 14 Canada: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 15 Canada: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 16 South America: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 17 South America: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 18 South America: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 19 Europe: Peptide and anticoagulant drugs Market, Type, 2018–2023, (USD Million)
Table 20 Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 21 Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 22 Western Europe: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 23 Western Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 24 Western Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 25 Eastern Europe: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 26 Eastern Europe: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 27 Eastern Europe: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 28 Asia-Pacific: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 29 Asia-Pacific: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 30 Asia-Pacific: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)
Table 31 Middle East & Africa: Peptide and anticoagulant drugs Market, by Type, 2018–2023, (USD Million)
Table 32 Middle East & Africa: Peptide and anticoagulant drugs Market, by Application, 2018–2023, (USD Million)
Table 33 Middle East & Africa: Peptide and anticoagulant drugs Market, by End-User, 2018–2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for the Global Peptide and anticoagulant drugs Market
Figure 3 Market Dynamics for the Global Peptide and anticoagulant drugs Market
Figure 4 Global Peptide and anticoagulant drugs Market Share, by Type 2017
Figure 6 Global Peptide and anticoagulant drugs Market Share, by Application, 2017
Figure 6 Global Peptide and anticoagulant drugs Market Share, by End-User, 2017
Figure 7 Global Peptide and anticoagulant drugs Market Share, by Region, 2017
Figure 8 North America Peptide and anticoagulant drugs Market Share, by Country, 2017
Figure 9 Europe Prescribed Health Apps Share, by Country, 2017
Figure 10 Asia-Pacific Peptide and anticoagulant drugs Market Share, by Country, 2017
Figure 11 Middle East & Africa Peptide and anticoagulant drugs Market Share, by Country, 2017
Figure 12 Global Peptide and anticoagulant drugs Market: Company Share Analysis, 2017 (%)
Figure 13 Abbott Laboratories Company: Key Financials
Figure 14 Abbott Laboratories Company: Segmental Revenue
Figure 15 Abbott Laboratories Company: Geographical Revenue
Figure 16 Cadila Pharmaceuticals: Key Financials
Figure 17 Cadila Pharmaceuticals: Segmental Revenue
Figure 18 Cadila Pharmaceuticals: Geographical Revenue
Figure 19 Sanofi S.A.: Key Financials
Figure 20 Sanofi S.A.: Segmental Revenue
Figure 21 Sanofi S.A.: Geographical Revenue
Figure 22 Eli Lilly and Company: Key Financials
Figure 23 Eli Lilly and Company: Segmental Revenue
Figure 24 Eli Lilly and Company: Geographical Revenue
Figure 25 Cipla Limited: Key Financials
Figure 26 Cipla Limited: Segmental Revenue
Figure 27 Cipla Limited: Geographical Revenue
Figure 28 Biocon Limited: Key Financials
Figure 29 Biocon Limited: Segmental Revenue
Figure 30 Biocon Limited: Geographical Revenue
Figure 31 Intas Pharmaceuticals Ltd.: Key Financials
Figure 32 Intas Pharmaceuticals Ltd.: Segmental Revenue
Figure 33 Intas Pharmaceuticals Ltd.: Geographical Revenue
Figure 34 Lupin Limited: Key Financials
Figure 35 Lupin Limited: Segmental Revenue
Figure 36 Lupin Limited: Geographical Revenue
Figure 37 Emcure Pharmaceuticals Ltd.: Key Financials
Figure 38 Emcure Pharmaceuticals Ltd.: Segmental Revenue
Figure 39 Sun Pharmaceutical Industries Ltd.: Key Financials
Figure 40 Sun Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 41 Sun Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 42 Novartis International AG: Key Financials
Figure 43 Novartis International AG: Segmental Revenue
Figure 44 Novartis International AG: Geographical Revenue